Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ortho Evra Label Update Includes Study Data On Blood Clot Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requests J&J conduct longer follow up studies on the risk of serious blood clots, heart attack and stroke associated with the birth control patch.

You may also be interested in...



Ortho Evra Adds More Blood Clot Warnings To Label

New epidemiology study supports previous findings of increased venous thromboembolism risk with J&J’s birth control patch.

Ortho Evra Adds More Blood Clot Warnings To Label

New epidemiology study supports previous findings of increased venous thromboembolism risk with J&J’s birth control patch.

J&J's Evra Canadian Label Includes Obesity, Sauna Warnings

Revised labeling on risk of venous thromboembolism associated with the birth control patch in Canada appears stronger than FDA's revision on Ortho Evra.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel